Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
6‑ethyl‑5‑[(2S)‑1‑(3‑methoxypropyl)‑2‑phenyl‑1,2,3,4-tetrahydroquinolin‑7‑yl]pyrimidine‐2,4‐diamine is a synthetic small molecule belonging to the phenylquinoline class. It features a quinoline moiety substituted with a phenyl group and targets the protein renin. Renin is an aspartic protease involved in the regulation of blood pressure via the renin‐angiotensin system. This compound has been studied as an experimental agent for its potential to inhibit renin activity but does not have any approved clinical indications or known marketed products[1][5][9]. Its primary mechanism of action is presumed to be direct inhibition of renin.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 6-ethyl-5-[(2S)-1-(3-methoxypropyl)-2-phenyl-1,2,3,4-tetrahydroquinolin-7-yl]pyrimidine-2,4-diamine.